Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab and Ibrutinib in Front Line Indolent Non-Hodgkin's Lymphoma
NCT03198026Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2018
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib, obinutuzumab in Non-Hodgkin lymphoma (NHL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2018; status: active, not recruiting.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
Non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03198026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198026.